Literature DB >> 15542714

Similarities between methamphetamine toxicity and proteasome inhibition.

F Fornai1, P Lenzi, M Gesi, M Ferrucci, G Lazzeri, L Capobianco, A de Blasi, G Battaglia, F Nicoletti, S Ruggieri, A Paparelli.   

Abstract

The monoamine neurotoxin methamphetamine (METH) is commonly used as an experimental model for Parkinson's disease (PD). In fact, METH-induced striatal dopamine (DA) loss is accompanied by damage to striatal nerve endings arising from the substantia nigra. On the other hand, PD is characterized by neuronal inclusions within nigral DA neurons. These inclusions contain alpha-synuclein, ubiquitin, and various components of a metabolic pathway named the ubiquitin-proteasome (UP) system, while mutation of genes coding for various components of the UP system is responsible for inherited forms of PD. In this presentation we demonstrate for the first time the occurrence of neuronal inclusions in vivo in the nigrostriatal system of the mouse following administration of METH. We analyzed, in vivo and in vitro, the shape and the fine structure of these neuronal bodies by using transmission electron microscopy. Immunocytochemical investigation showed that these METH-induced cytosolic inclusions stain for ubiquitin, alpha-synuclein, and UP-related molecules, thus sharing similar components with Lewy bodies occurring in PD, with an emphasis on enzymes belonging to the UP system. In line with this, blockade of this multicatalytic pathway by the selective inhibitor epoxomycin produced cell inclusions with similar features. Moreover, using a multifaceted pharmacological approach, we could demonstrate the need for endogenous DA in order to form neuronal inclusions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542714     DOI: 10.1196/annals.1316.021

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  19 in total

Review 1.  The role of autophagy in epileptogenesis and in epilepsy-induced neuronal alterations.

Authors:  Filippo Sean Giorgi; Francesca Biagioni; Paola Lenzi; Alessandro Frati; Francesco Fornai
Journal:  J Neural Transm (Vienna)       Date:  2014-09-14       Impact factor: 3.575

2.  Role of GSK3β/α-synuclein axis in methamphetamine-induced neurotoxicity in PC12 cells.

Authors:  Lizeng Li; Si Chen; Yue Wang; Xia Yue; Jingtao Xu; Weibing Xie; Pingming Qiu; Chao Liu; AiFeng Wang; Huijun Wang
Journal:  Toxicol Res (Camb)       Date:  2017-12-22       Impact factor: 3.524

3.  Chronic Methamphetamine Increases Alpha-Synuclein Protein Levels in the Striatum and Hippocampus but not in the Cortex of Juvenile Mice.

Authors:  B Butler; J Gamble-George; P Prins; A North; J T Clarke; H Khoshbouei
Journal:  J Addict Prev       Date:  2014

Review 4.  Neurotoxins and neurotoxicity mechanisms. An overview.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

5.  [Effect of methamphetamine exposure on S-nitrosylation of protein disulphide isomerase in PC12 cells].

Authors:  Xiao-Fang Wu; Ai-Feng Wang; Ping-Ming Qiu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-01-20

6.  Effects of maternal separation and methamphetamine exposure on protein expression in the nucleus accumbens shell and core.

Authors:  J J Dimatelis; V A Russell; D J Stein; W M Daniels
Journal:  Metab Brain Dis       Date:  2012-03-28       Impact factor: 3.584

Review 7.  Disease-Toxicant Interactions in Parkinson's Disease Neuropathology.

Authors:  Gunnar F Kwakye; Rachael A McMinimy; Michael Aschner
Journal:  Neurochem Res       Date:  2016-09-09       Impact factor: 3.996

Review 8.  Methamphetamine toxicity and messengers of death.

Authors:  Irina N Krasnova; Jean Lud Cadet
Journal:  Brain Res Rev       Date:  2009-03-25

9.  Proteomic analysis reveals differentially expressed proteins in the rat frontal cortex after methamphetamine treatment.

Authors:  J J Faure; S M Hattingh; D J Stein; W M Daniels
Journal:  Metab Brain Dis       Date:  2009-10-14       Impact factor: 3.584

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.